Your browser is no longer supported. Please, upgrade your browser.
GILD Gilead Sciences, Inc. monthly Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E61.85 EPS (ttm)0.96 Insider Own0.41% Shs Outstand1.26B Perf Week-2.30%
Market Cap75.23B Forward P/E8.94 EPS next Y6.66 Insider Trans-0.01% Shs Float1.25B Perf Month-0.85%
Income1.27B PEG1124.55 EPS next Q1.73 Inst Own80.20% Short Float1.82% Perf Quarter-9.23%
Sales23.15B P/S3.25 EPS this Y1.10% Inst Trans-1.45% Short Ratio2.42 Perf Half Y-23.55%
Book/sh13.90 P/B4.28 EPS next Y0.89% ROA2.10% Target Price73.92 Perf Year-11.56%
Cash/sh18.96 P/C3.14 EPS next 5Y0.06% ROE6.30% 52W Range57.04 - 85.97 Perf YTD-8.43%
Dividend2.72 P/FCF15.78 EPS past 5Y-10.50% ROI9.50% 52W High-30.79% Beta0.55
Dividend %4.57% Quick Ratio3.10 Sales past 5Y-2.00% Gross Margin79.00% 52W Low4.31% ATR1.32
Employees11800 Current Ratio3.30 Sales Q/Q17.40% Oper. Margin10.90% RSI (14)43.72 Volatility1.72% 2.21%
OptionableYes Debt/Eq1.68 EPS Q/Q131.00% Profit Margin5.50% Rel Volume0.89 Prev Close60.25
ShortableYes LT Debt/Eq1.59 EarningsOct 28 AMC Payout271.60% Avg Volume9.38M Price59.50
Recom2.50 SMA20-0.46% SMA50-3.32% SMA200-15.64% Volume8,320,539 Change-1.24%
Nov-03-20Resumed Morgan Stanley Equal-Weight $67
Oct-28-20Initiated UBS Neutral $61
Sep-30-20Resumed Jefferies Buy $78
Sep-15-20Upgrade Maxim Group Hold → Buy $88
Jul-31-20Reiterated Wells Fargo Equal Weight $87 → $76
Jul-31-20Reiterated SunTrust Hold $73 → $74
Jul-31-20Reiterated RBC Capital Mkts Outperform $89 → $87
Jul-31-20Reiterated Piper Sandler Overweight $90 → $85
Jul-31-20Reiterated Morgan Stanley Equal-Weight $80 → $79
Jul-31-20Reiterated Credit Suisse Neutral $75 → $73
Jul-20-20Upgrade Credit Suisse Underperform → Neutral $64 → $75
Jun-03-20Upgrade SVB Leerink Mkt Perform → Outperform $85 → $94
May-26-20Upgrade SunTrust Sell → Hold $73
May-01-20Downgrade SunTrust Hold → Sell $70
May-01-20Downgrade Raymond James Outperform → Mkt Perform
May-01-20Downgrade JP Morgan Overweight → Neutral
Apr-27-20Downgrade UBS Buy → Neutral $77 → $80
Apr-20-20Downgrade Wells Fargo Overweight → Equal Weight $87
Apr-20-20Downgrade BMO Capital Markets Outperform → Market Perform $79
Apr-17-20Downgrade CFRA Hold → Sell
Nov-25-20 01:16PM  
07:10AM  
Nov-24-20 01:21PM  
Nov-23-20 07:00PM  
11:02AM  
06:12AM  
Nov-22-20 06:30AM  
Nov-20-20 04:03PM  
01:39PM  
01:04PM  
12:37PM  
10:15AM  
09:35AM  
09:33AM  
08:46AM  
08:19AM  
07:09AM  
05:30AM  
Nov-19-20 09:31PM  
08:49PM  
08:12PM  
03:34PM  
09:35AM  
Nov-18-20 12:24PM  
08:35AM  
Nov-17-20 10:14AM  
Nov-16-20 01:54PM  
01:31PM  
02:02AM  
Nov-15-20 05:30PM  
Nov-13-20 04:13PM  
Nov-11-20 07:07AM  
06:00AM  
Nov-10-20 04:48PM  
10:28AM  
10:14AM  
07:26AM  
Nov-09-20 04:05PM  
03:15PM  
Nov-08-20 08:05AM  
Nov-07-20 06:06AM  
Nov-05-20 04:11PM  
10:35AM  
09:00AM  
Nov-04-20 04:05PM  
03:32PM  
02:25PM  
06:10AM  
06:01AM  
Nov-02-20 04:01PM  
12:26PM  
03:22AM  
03:17AM  
Nov-01-20 06:20AM  
Oct-31-20 06:55AM  
Oct-30-20 02:48PM  
09:46AM  
07:00AM  
Oct-29-20 03:20PM  
02:15PM  
02:03PM  
12:50PM  
10:14AM  
10:10AM  
09:27AM  
08:50AM  
06:40AM  
05:18AM  
03:03AM  
12:00AM  
Oct-28-20 11:34PM  
06:06PM  
05:45PM  
05:44PM  
05:22PM  
05:13PM  
04:14PM  
04:07PM  
04:02PM  
04:01PM  
02:30PM  
12:38PM  
10:24AM  
08:05AM  
07:34AM  
07:09AM  
06:55AM  
06:35AM  
02:36AM  
Oct-27-20 04:25PM  
11:59AM  
08:37AM  
08:16AM  
Oct-26-20 08:25PM  
01:06PM  
Oct-24-20 06:30AM  
Oct-23-20 07:17PM  
04:35PM  
04:33PM  
03:30PM  
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Whitley Richard JamesDirectorOct 01Option Exercise0.001,434031,122Oct 05 07:09 PM
Parsey MerdadChief Medical OfficerAug 17Sale68.3218212,4340Aug 19 12:53 PM
Mercier JohannaChief Commercial OfficerJul 24Option Exercise0.007,50507,505Jul 28 06:47 PM
Rodriguez JavierDirectorJun 23Sale75.5018914,2700Jun 25 01:51 PM
Dickinson Andrew DEVP, Chief Financial OfficerJun 10Option Exercise0.003,646015,046Jun 12 03:28 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMay 05Option Exercise39.7613,210525,22527,854May 07 06:02 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMay 05Sale79.2313,2101,046,64014,644May 07 06:02 PM
Cogan John FrancisDirectorMay 04Option Exercise19.632,41647,42657,276May 05 04:28 PM
Wilfong Diane E.SVP, Controller & CAOMay 04Option Exercise66.3611,486762,21123,685May 06 06:40 PM
Wilfong Diane E.SVP, Controller & CAOMay 04Sale80.0912,264982,22011,421May 06 06:40 PM
Cogan John FrancisDirectorMay 04Sale81.752,416197,50854,860May 05 04:28 PM
Cogan John FrancisDirectorApr 27Option Exercise19.632,41347,36757,273Apr 29 07:28 PM
Cogan John FrancisDirectorApr 27Sale79.902,413192,79954,860Apr 29 07:28 PM
Cogan John FrancisDirectorApr 20Option Exercise19.632,41347,36757,273Apr 21 07:42 PM
Cogan John FrancisDirectorApr 20Sale83.002,413200,27954,860Apr 21 07:42 PM
Cogan John FrancisDirectorApr 13Option Exercise19.632,41347,36757,273Apr 14 03:52 PM
Cogan John FrancisDirectorApr 13Sale75.902,413183,14754,860Apr 14 03:52 PM
Cogan John FrancisDirectorApr 06Option Exercise19.632,41347,36757,273Apr 07 05:34 PM
Cogan John FrancisDirectorApr 06Sale79.522,413191,88254,860Apr 07 05:34 PM
Cogan John FrancisDirectorMar 30Option Exercise19.632,41347,36757,273Mar 31 03:00 PM
Cogan John FrancisDirectorMar 30Sale75.352,413181,82054,860Mar 31 03:00 PM
Cogan John FrancisDirectorMar 23Option Exercise19.632,41347,36757,273Mar 24 08:42 PM
Cogan John FrancisDirectorMar 23Sale75.272,413181,62754,860Mar 24 08:42 PM
Cogan John FrancisDirectorMar 16Option Exercise19.632,41347,36757,273Mar 17 08:01 PM
Cogan John FrancisDirectorMar 16Sale67.262,413162,29854,860Mar 17 08:01 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 10Option Exercise24.302,95071,67017,594Mar 12 08:30 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 10Sale75.552,950222,87314,644Mar 12 08:30 PM
Cogan John FrancisDirectorMar 09Option Exercise19.632,41347,36757,273Mar 10 09:16 PM
Cogan John FrancisDirectorMar 09Sale77.972,413188,14254,860Mar 10 09:16 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 02Sale70.8810,441740,01414,644Mar 03 07:40 PM
Lofton Kevin EDirectorFeb 24Option Exercise19.6321,720426,36486,579Feb 25 05:13 PM
WILSON GAYLE EDirectorFeb 10Option Exercise19.6321,720426,364148,502Feb 11 07:02 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 10Option Exercise24.302,95071,67027,640Feb 12 06:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 10Sale69.322,950204,49424,690Feb 12 06:25 PM
WILSON GAYLE EDirectorFeb 10Sale67.7221,7201,470,878126,782Feb 11 07:02 PM
WOLD OLSEN PERDirectorFeb 07Option Exercise20.6520,282418,722118,136Feb 10 06:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 07Sale70.001,42699,82024,690Feb 10 07:00 PM
WOLD OLSEN PERDirectorFeb 07Sale69.0020,2821,399,45897,854Feb 10 06:25 PM
WOLD OLSEN PERDirectorFeb 06Option Exercise19.6321,720426,364119,574Feb 10 06:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 06Option Exercise40.565,000202,80029,690Feb 10 07:00 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 06Sale68.185,000340,90124,690Feb 10 07:00 PM
WOLD OLSEN PERDirectorFeb 06Sale68.1221,7201,479,60597,854Feb 10 06:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselJan 03Option Exercise24.302,95071,67020,014Jan 06 07:01 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselJan 03Sale64.632,950190,65917,064Jan 06 07:01 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselDec 03Option Exercise24.305,900143,34122,964Dec 04 07:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselDec 03Sale65.775,900388,04317,064Dec 04 07:11 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.